Doctor profile · Federal record
Dr. Saurabh Chhabra, M.D.
Hematology & Oncology Physician (CMS: Hematology/Oncology) · Hematology (Internal Medicine) Physician · Hematology (Internal Medicine) Physician · Hematology & Oncology Physician · Scottsdale, AZ
- NPI 1689837379
- Accepts Medicare
- MIPS 78.6 / 100 · 2023
- 24 yrs in practice
- Licensed in 4 states
- Male
- Group practice
- No sanctions
Practice & contact
Operates at 2 locations .
- Primary practice
-
13400 E Shea Blvd
Scottsdale, AZ 852595499
(480) 301-8000 - Additional location
-
9200 W Wisconsin Ave, Hematology and Oncology
Milwaukee, WI 532263522
(414) 805-4600
fax (414) 805-6815
Credentials & registration
- NPI registered
- July 2008 — 18 yrs on file
- Profile last updated
- September 22, 2022
- Year of graduation
- 2002 — 24 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State licenses (4)
- Arizona #67184 · South Carolina #34865 · California #A115644 · Wisconsin #66182
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1689837379. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
39,791
Distinct HCPCS
10
Medicare allowed
$1,186,957
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J9271 |
Injection, pembrolizumab, 1 mg | 7,200 | 31 | $54 | |
J9299 |
Injection, nivolumab, 1 mg | 7,040 | 16 | $30 | |
J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,660 | 34 | $48 | |
J1453 |
Injection, fosaprepitant, 1 mg | 6,300 | 42 | $0 | |
J9267 |
Injection, paclitaxel, 1 mg | 3,210 | 19 | $0 | |
J0897 |
Injection, denosumab, 1 mg | 2,100 | 20 | $23 | |
Q5119 |
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,130 | 16 | $28 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 902 | 89 | $0 | |
J2405 |
Injection, ondansetron hydrochloride, per 1 mg | 892 | 89 | $0 | |
J1569 |
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 810 | 16 | $45 |
In context: peer comparison
Among 28 peers in this city , average services per provider: 963. This provider delivers 41× the peer median.Open Payments
Industry payments received
All-time total
$17,938
Transactions
17
Manufacturers
8
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | 6 | $9,702.60 | |
| SOBI, INC | 2 | $2,975.00 | |
| Janssen Biotech, Inc. | 1 | $2,160.00 | |
| AstraZeneca Pharmaceuticals LP | 4 | $2,100.00 | |
| BeiGene USA, Inc. | 1 | $675.00 | |
| Janssen Scientific Affairs, LLC | 1 | $150.00 | |
| PFIZER INC. | 1 | $150.00 | |
| Celgene Corporation | 1 | $25.32 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
312
Patients
118
Total drug cost
$1,436,136
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Acyclovir | Generic | 68 | 29 | $1,661 |
| Revlimid (Lenalidomide) | Brand | 51 | 18 | $779,989 |
| Sulfamethoxazole-Trimethoprim (Sulfamethoxazole/Trimethoprim) | Brand | 38 | 15 | $452 |
| Dexamethasone | Generic | 36 | 21 | $732 |
| Lenalidomide | Generic | 28 | 0 | $398,256 |
| Prochlorperazine Maleate | Generic | 24 | 21 | $295 |
| Famotidine | Generic | 18 | 0 | $104 |
| Ondansetron Hcl | Generic | 14 | 14 | $195 |
| Hydromorphone Hcl | Generic | 12 | 0 | $173 |
| Pomalyst (Pomalidomide) | Brand | 12 | 0 | $254,130 |
Hospital affiliations
Frequently asked questions
What is Dr. Saurabh Chhabra's medical specialty?
Dr. Saurabh Chhabra practices Hematology & Oncology Physician in Scottsdale, AZ.
Where does Dr. Saurabh Chhabra practice?
Dr. Saurabh Chhabra practices at 13400 E Shea Blvd, Scottsdale, AZ 852595499. Office phone: 4803018000.
What is Dr. Saurabh Chhabra's NPI?
Dr. Saurabh Chhabra's National Provider Identifier (NPI) is 1689837379, issued by NPPES.
Does Dr. Saurabh Chhabra accept Medicare assignment?
Yes. Dr. Saurabh Chhabra accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Saurabh Chhabra commonly perform?
Top Medicare-reported procedures in 2023: Injection, pembrolizumab, 1 mg (HCPCS J9271); Injection, nivolumab, 1 mg (HCPCS J9299); Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS J9144). Source: CMS Medicare Physician & Other Practitioners file.